SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see code 9989/3.)
Neutropenia secondary to drug therapy, toxicexposure, infectious processes, immune mechanisms, or other causative factors must be excluded. The other myeloidcelllines do not show significant dysplasia.
For MDS diseases (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992), abstracting each of the subtypes would result in over-counting of the diseases.
1, Code only the first subtype that is diagnosed.
2. Do not change the histologycode or create a new abstract for any subsequent specific MDS subtypes.